Adora Ndu
Patrimonio netto: 838 456 $ in data 30/06/2026
Patrimonio netto: 838 456 $ in data 30/06/2026
La dottoressa Adora Ndu è VP-World Wide Research & Development alla BioMarin Pharmaceutical, Inc. Fa parte del consiglio di amministrazione di DBV Technologies SA. La dottoressa Ndu è stata precedentemente impiegata come membro dell'Università del Maryland. Ha conseguito la laurea presso l'Università del Maryland Francis King Carey School of Law e il dottorato presso l'Howard University College of Medicine.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 29/05/2026 | 32.908 ( 0,02% ) | 832 572 $ | 30/06/2026 | |
| 15/04/2026 | 1.825 ( 0% ) | 5 884 $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| DBV TECHNOLOGIES | Direttore/Membro del Consiglio | 19/05/2021 |
| BRIDGEBIO PHARMA, INC. | Consigliere Generale | 01/01/2022 |
| ACADIA PHARMACEUTICALS INC. | Direttore/Membro del Consiglio | 10/10/2022 |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine | Direttore/Membro del Consiglio | - |
| Società | Posizione | Fine |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2022 |
US Food & Drug Administration
US Food & Drug Administration General GovernmentGovernment Operates agencies to protect health and human services | Corporate Officer/Principal | 01/01/2016 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 8 |
|---|---|
BioMarin Pharmaceutical, Inc.
BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
ACADIA Pharmaceuticals, Inc.
ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
DBV Technologies SA
DBV Technologies SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that focuses on changing the field of immunotherapy | Health Technology |
US Food & Drug Administration
US Food & Drug Administration General GovernmentGovernment Operates agencies to protect health and human services | Government |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine | Health Services |
The University of Maryland Francis King Carey School of Law
The University of Maryland Francis King Carey School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Howard University College of Medicine
Howard University College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. BiotechnologyHealth Technology Develops medicines for genetic diseases to patients | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale